Faculty Profile
Dr. Ball
Edward Ball, M.D.
Professor of Medicine
Chief, Division of Bone Marrow Transplantation
Office Address:
Division of Bone Marrow Transplantation
University of California
Moores UCSD Cancer Center
3855 Health Sciences Drive, MC-0960
La Jolla, CA 93093
Office: (858) 822-6842
FAX: (858) 822-6844
Education and Training
| BS | Biochemistry, University of Maryland | 1968-1972 |
| MD | Case Western Reserve University | 1972-1976 |
| Resident | Hartford Hospital | 1976-1979 |
| Fellow | Hematology & Oncolog), University Hospitals of Cleveland | 1979-1981 |
| Fellow | Hematology & Oncology, Dartmouth- Hitchcock Medical Center | 1982-1983 |
Research Interests
Dr. Ball’s laboratory research focuses on the development of monoclonal antibody targeted immunotherapy, and its translation to the treatment of patients with malignancy. He has produced a large number of monoclonal antibodies of myeloid-associated antigens expressed on myeloid leukemia cells. These antibodies have been used clinically for the diagnosis and treatment of acute myeloid leukemia (AML). He has conducted a multi-center clinical trial using antibody-mediated purging using the AML cells from the marrow of patients with leukemia prior to transplantation, after high dose chemotherapy. He has developed in vivo therapeutics using first an anti-CD 15 antibody and, more recently, a bi-specific antibody. This bispecific antibody termed 251xH22 mediates antibody-directed cellular cytotoxicity (ADCC) of AML cells mediated by normal leukocyte cells including natural killer cells, monocytes and granulocytes. His laboratory has determined that there are direct signals transduced by binding of the anti-CD33 monoclonal antibody that lead to death of AML cells, and that the protein kinase Syk helps mediate this signal. This has led to an investigator-initiated clinical trial active at UCSD and two collaborating centers combining 5-azacytidine (that increases SyK expression) and the anti-CD33 monoclonal antibody Mylotarg. Another line of investigation involves using bifunctional antibody targeting gastrin-releasing peptide receptors on adenocarcinoma cells including prostate, breast, and lung cancers. This antibody triggers normal leukocyte ADCC against gastrin-releasing peptide receptor-positive cancer cells. In addition, Dr. Ball is principal investigator on numerous clinical trials active at UCSD Medical Center ranging from Phase I to Phase III trials. These clinical trials focus on leukemia and on important questions in stem cell transplantation. Dr. Ball represents UCSD on the Steering Committee of the NIH-sponsored BMT Clinical Trials Network, a network focused on addressing the major issues in hematopoietic stem cell transplantation.
Publications
Balaian L, Zhong R-K, Ball ED. The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or Zap-70 expression. Exp Hematol. 31:363-371, 2003
Zhong R-K, Law P, Wong D, Merzouk A, Salari H, Ball ED. Small peptide analogs to stromal derived factor-1 enhance chemotactic migration of human and mouse hematopoietic cells. Exp. Hematol. 32:470-475, 2004.
Balaian L, Ball ED. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia (AML) cells through similarities in their signaling pathways. Exp. Hematol. 33:199-211, 2005
Bashey A, Liu L, Ihasz A, Medina B, Corringham S, Keese K, Carrier E, Castro JE, Holman P, Lane TA, Hassidim K, Ball ED. Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged sixty or older. Leukemia Res. 30:503-506, 2006.
Zhong R-K, Loken M, Lane TA, Ball ED. CTLA-4 blockade by a human monoclonal antibody enhances the capacity of AML-derived dendric cells to induce T cell responses against AML cells in an autologous culture system. Cytotherapy 8:3-12, 2006.
Zhou J, Chen J, Zhong R-K, Mokotoff M, Shultz LD, Ball ED. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes. Clinical Cancer Res 12:2224-31, 2006.
Nguyen DH, Ball ED, Vargi A. Myeloid precursors and acute myeloid leukemia cells express multiple combinations of CD33-related siglecs: implications for diagnosis and immunotoxin therapy. Exp Hematol 34:728-35, 2006.
Ball Ed, Balaian L. Cytotoxic activity of gemtuzumap ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. Leukemia 20:2093-101, 2006.
Zhong RK, Lane TA, Ball ED. Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells. Exp Hematol 36:486-94, 2008
Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Streicher H, Lowy I, Solomon SR, Morris LE, Holland K, Mason J, Soiffer R, Ball ED. CTLA4 blockade with ipilimumab to great relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood, 2008 (in press).
Laboratory
[text here] |
||
Laboratory Personnel
|
||
| Name | Title | Laboratory Focus |
